AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation products, will release its financial results
for the fourth quarter and year ended December 31, 2008 on Thursday,
February 19, 2009.
AtriCure will host a conference call at 10:00 a.m. Eastern Time on
Thursday, February 19, 2009 to discuss its fourth quarter and full year
2008 financial results. A live web cast of the conference call will be
available online from the investor relations page of AtriCure’s
corporate web site at www.atricure.com.
Pre-registration is available for this call at the following URL:
https://www.theconferencingservice.com/prereg/key.process?key=PBEURJXKW
Pre-registering is recommended and only takes a few moments. You may
pre-register at any time, including up to and after the call start time.
Alternatively, if you prefer being placed into the call by an operator,
please call 888-679-8018 for domestic callers and 617-213-4845 for
international callers at least 15 minutes prior to the call start time
and use reservation number 85153861.
The web cast will remain available on AtriCure’s web site through March
21, 2009. A telephonic replay of the call will also be available until
March 19, 2009. The replay dial-in numbers are 888-286-8010 for domestic
callers and 617-801-6888 for international callers. Please use
reservation code 74400223.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart,
tissue. Medical journals have described the adoption by leading
cardiothoracic surgeons of the AtriCure Isolator® bipolar
ablation system as a treatment alternative during open-heart surgical
procedures to create lesions in cardiac tissue to block the abnormal
electrical impulses that cause atrial fibrillation, or AF, a rapid,
irregular quivering of the upper chambers of the heart. Additionally,
medical journals and leading cardiothoracic surgeons have described the
AtriCure Isolator® system as a promising treatment
alternative for patients who may be candidates for sole-therapy
minimally invasive procedures. AF affects more than 5.5 million people
worldwide and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator® system, including
its Isolator SynergyTM ablation clamps, and AtriCure’s
multifunctional pen and CoolrailTM linear ablation device,
for the ablation, or destruction, of cardiac tissue during surgical
procedures. Additionally, the FDA has cleared AtriCure’s multifunctional
pen for temporary pacing, sensing, stimulating and recording during the
evaluation of cardiac arrhythmias. To date, the FDA has not cleared or
approved AtriCure’s products for the treatment of AF. AtriCure’s left
atrial appendage clip system has not been approved for commercial use.
AtriCure, Inc.
Julie A. Piton, 513-755-4561
Vice
President and Chief Financial Officer
jpiton@atricure.com
